Buprenorphine Prescribing: To Expand or Not to Expand

被引:23
作者
Li, Xiaofan [1 ]
Shorter, Daryl [1 ,2 ]
Kosten, Thomas R. [1 ,2 ]
机构
[1] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA
[2] Michael E DeBakey VA Med Ctr, Houston, TX USA
关键词
buprenorphine; prescription opioids; abuse; diversion; regulation; policy; EXTENDED-RELEASE OXYCODONE; PRESCRIPTION MONITORING PROGRAMS; OFFICE-BASED TREATMENT; PRIMARY-CARE; OPIOID ANALGESICS; TREATMENT-SEEKING; OVERDOSE DEATHS; NONMEDICAL USE; MEDICAL USE; ABUSE;
D O I
10.1097/PRA.0000000000000154
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.
引用
收藏
页码:183 / 192
页数:10
相关论文
共 66 条
  • [1] Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users
    Alho, Hannu
    Sinclair, David
    Vuori, Erkki
    Holopainen, Antti
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2007, 88 (01) : 75 - 78
  • [2] [Anonymous], 2004, CLIN GUID US BUPR TR
  • [3] [Anonymous], 2017, DAT 2013 NAT SURV DR
  • [4] Safety, Effectiveness and Tolerance of Buprenorphine-Naloxone in the Treatment of Opioid Dependence: Results from a Nationwide Non-Interventional Study in Routine Care
    Apelt, S. M.
    Scherbaum, N.
    Goelz, J.
    Backmund, M.
    Soyka, M.
    [J]. PHARMACOPSYCHIATRY, 2013, 46 (03) : 94 - 107
  • [5] Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians
    Arfken, Cynthia L.
    Johanson, Chris-Ellyn
    di Menza, Salvatore
    Schuster, Charles Roberts
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2010, 39 (02) : 96 - 104
  • [6] Atluri S, 2014, PAIN PHYSICIAN, V17, pE119
  • [7] French field experience with buprenorphine
    Auriacombe, M
    Fatséas, M
    Dubernet, J
    Daulouède, JP
    Tignol, J
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 : S17 - S28
  • [8] Bujold Ed, 2012, J Opioid Manag, V8, P363, DOI 10.5055/jom.2012.0136
  • [9] Abuse Rates and Routes of Administration of Reformulated Extended-Release Oxycodone: Initial Findings From a Sentinel Surveillance Sample of Individuals Assessed for Substance Abuse Treatment
    Butler, Stephen F.
    Cassidy, Theresa A.
    Chilcoat, Howard
    Black, Ryan A.
    Landau, Craig
    Budman, Simon H.
    Coplan, Paul M.
    [J]. JOURNAL OF PAIN, 2013, 14 (04) : 351 - 358
  • [10] Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705